Kissei Pharmaceutical Partners with Viridian Therapeutics to Develop Thyroid Eye Disease Treatments in Japan
Kissei Pharmaceutical Co., Ltd. has entered a strategic partnership with Viridian Therapeutics to develop and commercialize treatments for thyroid eye disease in Japan, valued at up to $385 million.
- Kissei Pharmaceutical Co Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read